Clinical

Dataset Information

0

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer


ABSTRACT: This is a Phase II multi-center 2-sequential cohorts trial, designed to assess the objective response rate of two anti HER2 combination in advanced disease CRC patients harbouring an amplified HER2 tumor assessed according to HERACLES Diagnostic Criteria by FISH/SISH. Cohort A: monoclonal antibody trastuzumab, used in combination with the small molecule tyrosine kinase inhibitor lapatinib. Cohort B, monoclonal antibody pertuzumab, used in combination with the antibody drug conjugate trastuzumab-emtansine. Please note that cohort A accrual has been closed and endpoint already reached.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms Malignant,Metastatic Colorectal Carcinoma (mcrc),Colorectal Neoplasms,Carcinoma Metastatico Del Colon-retto

PROVIDER: 2249965 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2012-05-02 | E-GEOD-31432 | biostudies-arrayexpress
2020-01-26 | GSE121105 | GEO
2021-08-24 | GSE181574 | GEO
2019-12-31 | GSE89216 | GEO
2012-05-03 | GSE31432 | GEO
2022-11-04 | GSE122426 | GEO
2018-08-29 | GSE110189 | GEO
| PRJNA495653 | ENA
2020-03-05 | GSE146380 | GEO
2016-03-31 | E-GEOD-62327 | biostudies-arrayexpress